NCT00413790View on ClinicalTrials.gov

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

September 30, 2007

Conditions
Healthy
Interventions
DRUG

Darifenacin

Darifenacin tablets 15 mg once daily

DRUG

Tolterodine

Tolterodine extended release (ER) 4 mg once daily

DRUG

Placebo

Placebo tablet once daily

Trial Locations (12)

14202

Investigative Site, Buffalo

32216

Investigative Site, Jacksonville

33458

Investigative Site, Jupiter

42431

Investigative Site, Madisonville

66215

Investigative Site, Overland Park

75235

Investigative Site, Dallas

78752

Investigative Site, Austin

85251

Investigative Site, Scottsdale

85282

Investigative Site, Tempe

92103

Investigative Site, San Diego

02481

Investigative Site, Wellesley Hills

07601

Investigative Site, Hackensack

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
collaborator

Procter and Gamble

INDUSTRY

lead

Novartis

INDUSTRY